

# Frank Edelmann

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9288966/frank-edelmann-publications-by-citations.pdf>  
**Version:** 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

96 papers	3,824 citations	27 h-index	61 g-index
102 ext. papers	5,347 ext. citations	6.7 avg, IF	4.87 L-index

#	Paper	IF	Citations
96	Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 781-91	27.4	457
95	Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 58, 1780-91	15.1	406
94	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , <b>2019</b> , 40, 3297-3317	9.5	379
93	Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. <i>Lancet, The</i> , <b>2018</b> , 392, 1047-1057	40	262
92	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <i>European Heart Journal</i> , <b>2014</b> , 35, 2797-815	9.5	231
91	Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 2683-93	27.4	145
90	Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. <i>European Journal of Heart Failure</i> , <b>2011</b> , 13, 670-80	12.3	124
89	Potential Usefulness and Clinical Relevance of Adding Left Atrial Strain to Left Atrial Volume Index in the Detection of Left Ventricular Diastolic Dysfunction. <i>JACC: Cardiovascular Imaging</i> , <b>2018</b> , 11, 1405-1415	8.4	103
88	Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 214-23	12.3	100
87	A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 874-883	7.9	91
86	The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 1309-16	12.3	89
85	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 391-412	12.3	84
84	Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. <i>Clinical Research in Cardiology</i> , <b>2011</b> , 100, 755-64	6.1	80
83	Myocardial hypertrophy and its role in heart failure with preserved ejection fraction. <i>Journal of Applied Physiology</i> , <b>2015</b> , 119, 1233-42	3.7	74
82	Galectin-3 in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1095-101	12.3	72
81	Normal range and usefulness of right ventricular systolic strain to detect subtle right ventricular systolic abnormalities in patients with heart failure: a multicentre study. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2017</b> , 18, 212-223	4.1	70
80	Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. <i>European Heart Journal</i> , <b>2012</b> , 33, 203-12	9.5	63

79	Effects of exercise training on different quality of life dimensions in heart failure with preserved ejection fraction: the Ex-DHF-P trial. <i>European Journal of Preventive Cardiology</i> , <b>2015</b> , 22, 582-93	3.9	60
78	Rationale and design of the Aldosterone receptor blockade in diastolic heart failure trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 874-82	12.3	50
77	Left ventricular longitudinal systolic function analysed by 2D speckle-tracking echocardiography in heart failure with preserved ejection fraction: a meta-analysis. <i>Open Heart</i> , <b>2017</b> , 4, e000630	3	42
76	Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1290-1299	12.3	42
75	Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. <i>Clinical Research in Cardiology</i> , <b>2008</b> , 97, 578-86	6.1	42
74	Effect of High-Intensity Interval Training, Moderate Continuous Training, or Guideline-Based Physical Activity Advice on Peak Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 325, 542-554	27.4	39
73	Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 140-149	7.9	38
72	A network against failing hearts--introducing the German "Competence Network Heart Failure". <i>International Journal of Cardiology</i> , <b>2010</b> , 145, 135-8	3.2	32
71	Associations of methylarginines and homoarginine with diastolic dysfunction and cardiovascular risk factors in patients with preserved left ventricular ejection fraction. <i>Journal of Cardiac Failure</i> , <b>2014</b> , 20, 923-30	3.3	28
70	Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. <i>International Journal of Cardiology</i> , <b>2013</b> , 169, 408-17	3.2	27
69	Exercise training in Diastolic Heart Failure (Ex-DHF): rationale and design of a multicentre, prospective, randomized, controlled, parallel group trial. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1067-1074	12.3	25
68	Impaired physical quality of life in patients with diastolic dysfunction associates more strongly with neurohumoral activation than with echocardiographic parameters: quality of life in diastolic dysfunction. <i>American Heart Journal</i> , <b>2011</b> , 161, 797-804	4.9	25
67	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart TOMicsTin AGEing (HOMAGE) randomized clinical trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 684-696	9.5	23
66	Clinical Relevance of Left Atrial Strain to Predict Recurrence of Atrial Fibrillation after Catheter Ablation: A Meta-Analysis. <i>Echocardiography</i> , <b>2016</b> , 33, 724-33	1.5	21
65	Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 92-113	12.3	21
64	Natriuretic peptides for the detection of paroxysmal atrial fibrillation. <i>Open Heart</i> , <b>2015</b> , 2, e000182	3	20
63	Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH). <i>ESC Heart Failure</i> , <b>2018</b> , 5, 830-841	3.7	20
62	Diastolic stress test echocardiography in patients with suspected heart failure with preserved ejection fraction: a pilot study. <i>ESC Heart Failure</i> , <b>2019</b> , 6, 146-153	3.7	19

61	Diagnosis of heart failure with preserved ejection fraction. <i>Heart Failure Clinics</i> , <b>2014</b> , 10, 399-406	3.3	18
60	Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study. <i>ESC Heart Failure</i> , <b>2018</b> , 5, 288-296	3.7	17
59	Vitamin D deficiency in patients with diastolic dysfunction or heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , <b>2019</b> , 6, 262-270	3.7	16
58	Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial). <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 460-470	12.3	16
57	OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 127-135	12.3	16
56	Chronic Heart Failure. <i>Deutsches Arzteblatt International</i> , <b>2018</b> , 115, 124-130	2.5	16
55	Arterial stiffness and elevated left ventricular filling pressure in patients at risk for the development or a previous diagnosis of HF-A subgroup analysis from the DIAST-CHF study. <i>Journal of the American Society of Hypertension</i> , <b>2017</b> , 11, 303-313		13
54	Higher plasma levels of MR-pro-atrial natriuretic peptide are linked to less anxiety: results from the observational DIAST-CHF study. <i>Clinical Research in Cardiology</i> , <b>2015</b> , 104, 574-81	6.1	13
53	CMR Tissue Characterization in Patients with HFmrEF. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	13
52	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 268-277	7.9	13
51	Lower limit of normality and clinical relevance of left ventricular early diastolic strain rate for the detection of left ventricular diastolic dysfunction. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2018</b> , 19, 905-915	4.1	13
50	Prognostic impact of diastolic dysfunction in systolic heart failure-A cross-project analysis from the German Competence Network Heart Failure. <i>Clinical Cardiology</i> , <b>2017</b> , 40, 667-673	3.3	12
49	Should procalcitonin be measured routinely in acute decompensated heart failure?. <i>Biomarkers in Medicine</i> , <b>2015</b> , 9, 651-9	2.3	12
48	Early detection of cardiac alterations by left atrial strain in patients with risk for cardiac abnormalities with preserved left ventricular systolic and diastolic function. <i>International Journal of Cardiovascular Imaging</i> , <b>2018</b> , 34, 701-711	2.5	12
47	Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 706-712	16.2	12
46	Predictive value of metabolomic biomarkers for cardiovascular disease risk: a systematic review and meta-analysis. <i>Biomarkers</i> , <b>2020</b> , 25, 101-111	2.6	11
45	Poor self-rated health predicts mortality in patients with stable chronic heart failure. <i>European Journal of Cardiovascular Nursing</i> , <b>2016</b> , 15, 504-512	3.3	11
44	Range Variability in CMR Feature Tracking Multilayer Strain across Different Stages of Heart Failure. <i>Scientific Reports</i> , <b>2019</b> , 9, 16478	4.9	11

43	Determinants of change in quality of life in the Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD). <i>European Journal of Internal Medicine</i> , <b>2013</b> , 24, 333-8	3.9	11
42	Effects of long-term endurance and resistance training on diastolic function, exercise capacity, and quality of life in asymptomatic diastolic dysfunction vs. heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , <b>2014</b> , 1, 59-74	3.7	11
41	Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study. <i>BMC Cardiovascular Disorders</i> , <b>2020</b> , 20, 408	2.3	11
40	Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 326, 1919-1929	27.4	10
39	Amount or intensity? Potential targets of exercise interventions in patients with heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , <b>2018</b> , 5, 53-62	3.7	10
38	Motivational interviewing can support physical activity in elderly patients with diastolic heart failure: results from a pilot study. <i>ESC Heart Failure</i> , <b>2019</b> , 6, 658-666	3.7	8
37	The diagnostic and prognostic value of galectin-3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST-CHF study. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 829-841	3.7	8
36	Exercise training in patients with a left ventricular assist device (Ex-VAD): rationale and design of a multicentre, prospective, assessor-blinded, randomized, controlled trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1152-1159	12.3	7
35	Plasma mid-regional pro-adrenomedullin levels are inversely associated with anxiety but unrelated to depression: Results from the observational DIAST-CHF study in patients with cardiovascular risk factors. <i>Psychoneuroendocrinology</i> , <b>2015</b> , 62, 227-32	5	6
34	NT-proBNP and diastolic left ventricular function in patients with Marfan syndrome. <i>IJC Heart and Vasculature</i> , <b>2016</b> , 12, 15-20	2.4	6
33	Lipid Metabolite Biomarkers in Cardiovascular Disease: Discovery and Biomechanism Translation from Human Studies. <i>Metabolites</i> , <b>2021</b> , 11,	5.6	6
32	Rationale and study design of OUTSTEP-HF: a randomised controlled study to assess the effect of sacubitril/valsartan and enalapril on physical activity measured by accelerometry in patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1724-1733	12.3	5
31	Heart failure therapy in diabetic patients-comparison with the recent ESC/EASD guideline. <i>Cardiovascular Diabetology</i> , <b>2011</b> , 10, 15	8.7	5
30	Incremental prognostic value of a novel metabolite-based biomarker score in congestive heart failure patients. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 3029-3039	3.7	5
29	Morbidity and mortality in patients with cardiovascular risk factors and obstructive sleep apnoea: results from the DIAST-CHF cohort. <i>Respiratory Medicine</i> , <b>2019</b> , 154, 127-132	4.6	4
28	Economic impact of heart failure with preserved ejection fraction: insights from the ALDO-DHF trial. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 786-793	3.7	4
27	Inferior vena cava ultrasound in acute decompensated heart failure: design rationale of the CAVA-ADHF-DZHK10 trial. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 973-983	3.7	4
26	Elevated Plasma C-Terminal Endothelin-1 Precursor Fragment Concentrations Are Associated with Less Anxiety in Patients with Cardiovascular Risk Factors. Results from the Observational DIAST-CHF Study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0136739	3.7	4

25	Proteomics to improve phenotyping in obese patients with heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1633-1644	12.3	4
24	Left atrial function and maximal exercise capacity in heart failure with preserved and mid-range ejection fraction. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 116-128	3.7	4
23	miR-181c level predicts response to exercise training in patients with heart failure and preserved ejection fraction: an analysis of the OptimEx-Clin trial. <i>European Journal of Preventive Cardiology</i> , <b>2021</b> ,	3.9	4
22	Higher plasma levels of CT-proAVP are linked to less anxiety in men but not women with cardiovascular risk factors: Results from the observational Diast-CHF study. <i>Psychoneuroendocrinology</i> , <b>2019</b> , 101, 272-277	5	3
21	Heterogeneous Metabolic Response to Exercise Training in Heart Failure with Preserved Ejection Fraction. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	3
20	Variability of Myocardial Strain During Isometric Exercise in Subjects With and Without Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , <b>2020</b> , 7, 111	5.4	3
19	Left atrial strain predicts exercise capacity in heart failure independently of left ventricular ejection fraction.. <i>ESC Heart Failure</i> , <b>2022</b> ,	3.7	3
18	NT-proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	3
17	Serum creatinine and cystatin C-based estimates of glomerular filtration rate are misleading in acute heart failure. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 3070-3081	3.7	3
16	Discordance between estimated and measured changes in plasma volume among patients with acute heart failure. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	3
15	Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	2
14	Anti- $\beta$ -Adrenoreceptor auto-Antibodies in elderly heart failure patients. <i>Frontiers in Bioscience - Landmark</i> , <b>2019</b> , 24, 1037-1049	2.8	2
13	Performance of a cardiac lipid panel compared to four prognostic scores in chronic heart failure. <i>Scientific Reports</i> , <b>2021</b> , 11, 8164	4.9	2
12	Myocardial deformation assessed among heart failure entities by cardiovascular magnetic resonance imaging. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 890-897	3.7	2
11	Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients: the Aldo-DHF randomized controlled trial. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 1	6.1	2
10	Syncopes and clinical outcome in heart failure: results from prospective clinical study data in Germany. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 942-952	3.7	1
9	Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction. <i>Cardiac Failure Review</i> , <b>2020</b> , 6, 1-7	4.2	1
8	A Random Shuffle Method to Expand a Narrow Dataset and Overcome the Associated Challenges in a Clinical Study: A Heart Failure Cohort Example. <i>Frontiers in Cardiovascular Medicine</i> , <b>2020</b> , 7, 599923	5.4	1

7	Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> ,	6.4	1
6	Estimating fat mass in heart failure patients. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , <b>2016</b> , 1, e78-e89	0.9	1
5	Iron Deficiency Impacts Diastolic Function, Aerobic Exercise Capacity, and Patient Phenotyping in Heart Failure With Preserved Ejection Fraction: A Subanalysis of the OptimEx-Clin Study.. <i>Frontiers in Physiology</i> , <b>2021</b> , 12, 757268	4.6	0
4	Outcome assessment using estimation of left ventricular filling pressure in asymptomatic patients at risk for heart failure with preserved ejection fraction. <i>IJC Heart and Vasculature</i> , <b>2020</b> , 28, 100525	2.4	0
3	Erhalt von Leistungsfähigkeit und Lebensqualität bei chronischer Herzinsuffizienz. <i>Kardiologe</i> , <b>2022</b> , 16, 185-196	0.6	0
2	Higher galectin-3 levels are independently associated with lower anxiety in patients with risk factors for heart failure. <i>BioPsychoSocial Medicine</i> , <b>2020</b> , 14, 24	2.8	
1	Utilization of galectin-3 in case management across the spectrum of heart failure. <i>Reviews in Cardiovascular Medicine</i> , <b>2014</b> , 15, 197-207	3.9	